Comparison and predictors of rash associated with 15 antiepileptic drugs

Neurology

Volumn 68, Issue 20, 2007, Pages 1701-1709

  Arif, H ^a   Buchsbaum, R ^b   Weintraub, D ^a   Koyfman, S ^a   Salas Humara, C ^a   Bazil, C W ^a   Resor Jr , S R ^a   Hirsch, L J ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Neurological Institute ^*  (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTICONVULSANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TOXICITY; BRAIN DISEASE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EPILEPTIC STATE; FEMALE; FEVER; FOCAL EPILEPSY; GENDER; GENERALIZED EPILEPSY; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; LEUKOPENIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE ANALYSIS; NEUTROPENIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; ANTICONVULSANTS; COMORBIDITY; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EPILEPSY; EXANTHEMA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; STEVENS-JOHNSON SYNDROME;

EID: 34248531953     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000261917.83337.db     Document Type: Article

References (26)

1. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-155.
2. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002;22:27-39.
3. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
4. Chadwick D, Shaw MD, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry 1984;47:642-644.
5. Kramlinger KG, Phillips KA, Post RM. Rash complicating carbamazepine treatment. J Clin Psychopharmacol 1994;14:408-413.
6. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-771.
7. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151.
8. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 1994;57:682-687.
9. Beydoun A, Sachdeo RC, Kutluay E, McCague K, D'Souza J. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy.Epilepsia2003;44:1160-1165.
10. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-1019.
11. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-991.
12. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-607.
13. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345:476-479.
14. Richens A. Safety of lamotrigine. Epilepsia 1994;35 (suppl 5):S37-S40.
15. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-1873.
16. Faught E, Morris G, Jacobson M, et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 1999;40:1135-1140.
17. Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JW. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996;54:47-49.
18. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037-1042.
19. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 2005;62:1432-1436.
20. Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia 2006;47:318-322.
21. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-546.
22. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-1138.
23. Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997;24:245-249.
24. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986;256:3358-3363.
25. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003;90:342-347.
26. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-1635.